Toll-like receptor 9 agonists promote IL-8 and TGF-β1production via activation of nuclear factor κB in PC-3 cells

被引:37
作者
Di, Jin-ming [1 ]
Pang, Jun [1 ]
Pu, Xiao-yong [1 ]
Zhang, Yan [1 ]
Liu, Xiao-peng [1 ]
Fang, You-qiang [1 ]
Ruan, Xing-xing [1 ]
Gao, Xin [1 ]
机构
[1] Sun Yat Sen Univ, Affiliated Hosp 3, Dept Urol, Guangzhou 510630, Guangdong, Peoples R China
基金
中国国家自然科学基金; 高等学校博士学科点专项科研基金;
关键词
PROSTATE-CANCER CELLS; CPG-OLIGODEOXYNUCLEOTIDES; LUNG-CANCER; RADICAL PROSTATECTOMY; HELICOBACTER-PYLORI; EXPRESSION; INFLAMMATION; TLR9; ANGIOGENESIS; APOPTOSIS;
D O I
10.1016/j.cancergencyto.2009.03.006
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Chronic infection and resulting inflammation promote tumor development and progression, and Toll-like receptors (TLRs) may play an important role in this process. The aim of this study was to determine whether CpG oligonucleotides (CpG-ODN), which are Toll-like receptor 9 (TLR9) agonists, can promote inflammatory cytokines release from the prostate cancer PC-3 cells through activation of nuclear factor-kappa B (NF-kappa B). Flow cytometry, semiquantitative real-time reverse transcriptase-polymerase chain reaction, enzyme-linked immunosorbent assay, and immunofluorescence analysis were used to detect the transforming growth factor-beta 1 (TGF-beta 1) and interleukin-8 (IL-8) release and NF-kappa B activation in PC-3 cells after CpG-ODN stimulation. CpG-ODN promoted the expression and secretion of immunosuppressive cytokines TGF-beta 1 and IL-8 from PC-3 cells. In addition, after CpG-ODN stimulation, NF-kappa B nuclear translocation was also observed in PC-3 cells, contributing to CpG-induced upregulation of IL-8 and TGF-beta 1. Thus, TLR9 agonists may promote IL-8 and TGF-beta 1 production in human prostate cancer cells through NF-kappa B activation. (C) 2009 Elsevier Inc. All rights reserved.
引用
收藏
页码:60 / 67
页数:8
相关论文
共 33 条
[1]   CpG oligodeoxynucleotides induce cyclooxygenase-2 in human B lymphocytes: Implications for adjuvant activity and antibody production [J].
Bernard, Matthew P. ;
Phipps, Richard P. .
CLINICAL IMMUNOLOGY, 2007, 125 (02) :138-148
[2]   Helicobacter pylori-induced invasion and angiogenesis of gastric cells is mediated by cyclooxygenase-2 induction through TLR2/TLR9 and promoter regulation [J].
Chang, YJ ;
Wu, MS ;
Lin, JT ;
Chen, CC .
JOURNAL OF IMMUNOLOGY, 2005, 175 (12) :8242-8252
[3]   Inflammation and cancer [J].
Coussens, LM ;
Werb, Z .
NATURE, 2002, 420 (6917) :860-867
[4]   Inflammatory cells and cancer: Think different! [J].
Coussens, LM ;
Werb, Z .
JOURNAL OF EXPERIMENTAL MEDICINE, 2001, 193 (06) :F23-F26
[5]   Chronic bacterial infection and inflammation incite reactive hyperplasia in a mouse model of chronic prostatitis [J].
Elkahwaji, Johny E. ;
Zhong, Weixiong ;
Hopkins, Walter J. ;
Bushman, Wade .
PROSTATE, 2007, 67 (01) :14-21
[6]   Comparison of human B cell activation by TLR7 and TLR9 agonists [J].
Hanten, John A. ;
Vasilakos, John P. ;
Riter, Christie L. ;
Neys, Lori ;
Lipson, Kenneth E. ;
Alkan, Sefik S. ;
Birmachu, Woubalem .
BMC IMMUNOLOGY, 2008, 9 (1)
[7]   TLR4 signaling promotes immune escape of human lung cancer cells by inducing immunosuppressive cytokines and apoptosis resistance [J].
He, Weigang ;
Liu, Qiuyan ;
Wang, Li ;
Chen, Wei ;
Li, Nan ;
Cao, Xuetao .
MOLECULAR IMMUNOLOGY, 2007, 44 (11) :2850-2859
[8]   Toll like receptor-9 agonists stimulate prostate cancer invasion in vitro [J].
Ilvesaro, Joanna M. ;
Merrell, Melinda A. ;
Swain, Telisha Millender ;
Davidson, Jennifer ;
Zayzafoon, Majd ;
Harris, Kevin W. ;
Selander, Katri S. .
PROSTATE, 2007, 67 (07) :774-781
[9]   High-grade inflammation in prostate cancer as a prognostic factor for biochemical recurrence after radical prostatectomy [J].
Irani, J ;
Goujon, JM ;
Ragni, E ;
Peyrat, L ;
Hubert, J ;
Saint, F ;
Mottet, N .
UROLOGY, 1999, 54 (03) :467-472
[10]   Pathogen-associated molecular patterns are growth and survival factors for human myeloma cells through Toll-like receptors [J].
Jego, G ;
Bataille, R ;
Geffroy-Luseau, A ;
Descamps, G ;
Pellat-Deceunynck, C .
LEUKEMIA, 2006, 20 (06) :1130-1137